Literature DB >> 8541871

Familial hypertrophic cardiomyopathy: a genetic model of cardiac hypertrophy.

H Watkins1, J G Seidman, C E Seidman.   

Abstract

Familial hypertrophic cardiomyopathy is an autosomal dominant disorder manifesting as cardiac hypertrophy in the absence of increased cardiac work load, which has been studied as a model of myocardial hypertrophy in humans. Hypertrophic cardiomyopathy is genetically heterogeneous with three known disease-genes and two further mapped loci. The disease-genes encode contractile proteins of the thick and thin filaments of the sarcomere: the beta cardiac myosin heavy chain gene on chromosome 14q11, the alpha tropomyosin gene on chromosome 15q2 and the cardiac troponin T gene on chromosome 1q3. Other disease loci have been mapped to chromosome 11p13-q13 and 7q3. In each known disease-gene a number of different mutations have been identified; these are missense mutations, or mutations leading to modest alterations of peptide structure, but not null alleles. Specific mutations are associated with different disease severity and may provide diagnostic and prognostic information not available from clinical assessment. Genetic and functional data suggest that mutations which cause hypertrophic cardiomyopathy act as dominant negative alleles that impair cross-bridge cycling and contractile function and interfere with sarcomere assembly.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8541871     DOI: 10.1093/hmg/4.suppl_1.1721

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  25 in total

1.  Factors contributing to troponin exchange in myofibrils and in solution.

Authors:  M She; D Trimble; L C Yu; J M Chalovich
Journal:  J Muscle Res Cell Motil       Date:  2000       Impact factor: 2.698

Review 2.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

3.  Myosin VIIA mutation screening in 189 Usher syndrome type 1 patients.

Authors:  M D Weston; P M Kelley; L D Overbeck; M Wagenaar; D J Orten; T Hasson; Z Y Chen; D Corey; M Mooseker; J Sumegi; C Cremers; C Moller; S G Jacobson; M B Gorin; W J Kimberling
Journal:  Am J Hum Genet       Date:  1996-11       Impact factor: 11.025

Review 4.  The phenotype/genotype relation and the current status of genetic screening in hypertrophic cardiomyopathy, Marfan syndrome, and the long QT syndrome.

Authors:  J Burn; J Camm; M J Davies; L Peltonen; P J Schwartz; H Watkins
Journal:  Heart       Date:  1997-08       Impact factor: 5.994

5.  Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy. Evidence for a dominant negative action.

Authors:  H Watkins; C E Seidman; J G Seidman; H S Feng; H L Sweeney
Journal:  J Clin Invest       Date:  1996-12-01       Impact factor: 14.808

6.  Functional analysis of myosin mutations that cause familial hypertrophic cardiomyopathy.

Authors:  O Roopnarine; L A Leinwand
Journal:  Biophys J       Date:  1998-12       Impact factor: 4.033

7.  Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function.

Authors:  H L Sweeney; H S Feng; Z Yang; H Watkins
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

8.  Functional studies of yeast actin mutants corresponding to human cardiomyopathy mutations.

Authors:  W W Wong; T C Doyle; P Cheung; T M Olson; E Reisler
Journal:  J Muscle Res Cell Motil       Date:  2001       Impact factor: 2.698

9.  Myosin-driven rescue of contractile reserve and energetics in mouse hearts bearing familial hypertrophic cardiomyopathy-associated mutant troponin T is mutation-specific.

Authors:  Huamei He; Kirsten Hoyer; Hai Tao; Ronald Rice; Jesus Jimenez; Jil C Tardiff; Joanne S Ingwall
Journal:  J Physiol       Date:  2012-08-20       Impact factor: 5.182

10.  Normal passive viscoelasticity but abnormal myofibrillar force generation in human hypertrophic cardiomyopathy.

Authors:  Anita C Hoskins; Adam Jacques; Sonya C Bardswell; William J McKenna; Victor Tsang; Cristobal G dos Remedios; Elisabeth Ehler; Kim Adams; Shapour Jalilzadeh; Metin Avkiran; Hugh Watkins; Charles Redwood; Steven B Marston; Jonathan C Kentish
Journal:  J Mol Cell Cardiol       Date:  2010-07-06       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.